Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487695 | 1.00 | NFE2L2 (0.35) | NFE2L2KEAP1HCAR2AKR1B10AKR1B1 | |
| SCHEMBL11386860 | 0.88 | — | — | |
| SCHEMBL6916368 | 0.88 | — | — | |
| SCHEMBL7643942 | 0.88 | — | — | |
| SCHEMBL11342877 | 0.86 | — | — | |
| SCHEMBL11342881 | 0.86 | — | — | |
| SCHEMBL11382181 | 0.86 | — | — | |
| SCHEMBL29094851 | 0.84 | — | — | |
| SCHEMBL11551166 | 0.84 | POLB (0.52) | NFE2L2KEAP1HCAR2GSK3BALDH1A1 | |
| SCHEMBL15499092 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064720-A1 | Dietary Supplement Compositions and Methods of Making and Using the Same | AMATO DANIEL MOSES | 2011-03-17 | — | — | US | disclosed |
| US-20110064712-A1 | Dietary Supplement Compositions and Methods of Making and Using the Same | AMATO DANIEL MOSES | 2011-03-17 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064720-A1 | Dietary Supplement Compositions and Methods of Making and Using the Same | SLC5A6, PNLIP, LIPC | NFE2L2 2504/4885KEAP1 2082/4885HCAR2 2542/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | NFE2L2 75/4885KEAP1 107/4885HCAR2 414/4885 |
| US-20110064712-A1 | Dietary Supplement Compositions and Methods of Making and Using the Same | SLC5A6, PNLIP, LIPC | NFE2L2 2504/4885KEAP1 2082/4885HCAR2 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.